{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "Parkinson\u2019s disease", "antagonist", "biological activity", "functionalization", "heterocyclic", "inhibitor", "neurodegeneration", "pyrazole", "synthesis"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33668128", "DateCompleted": {"Year": "2021", "Month": "04", "Day": "07"}, "DateRevised": {"Year": "2021", "Month": "04", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "02", "Day": "24"}], "Language": ["eng"], "ELocationID": ["1202", "10.3390/molecules26051202"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "26", "Issue": "5", "PubDate": {"Year": "2021", "Month": "Feb", "Day": "24"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Pyrazole Scaffold Synthesis, Functionalization, and Applications in Alzheimer's Disease and Parkinson's Disease Treatment (2011-2020).", "Abstract": {"AbstractText": ["The remarkable prevalence of pyrazole scaffolds in a versatile array of bioactive molecules ranging from apixaban, an anticoagulant used to treat and prevent blood clots and stroke, to bixafen, a pyrazole-carboxamide fungicide used to control diseases of rapeseed and cereal plants, has encouraged both medicinal and organic chemists to explore new methods in developing pyrazole-containing compounds for different applications. Although numerous synthetic strategies have been developed in the last 10 years, there has not been a comprehensive overview of synthesis and the implication of recent advances for treating neurodegenerative disease. This review first presents the advances in pyrazole scaffold synthesis and their functionalization that have been published during the last decade (2011-2020). We then narrow the focus to the application of these strategies in the development of therapeutics for neurodegenerative diseases, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD)."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Radiology, Washington University School of Medicine, 510 S. Kingshighway Boulevard St. Louis, MO, 63110, USA."}], "LastName": "Li", "ForeName": "Xuefei", "Initials": "X"}, {"Identifier": ["0000-0002-6687-9850"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Radiology, Washington University School of Medicine, 510 S. Kingshighway Boulevard St. Louis, MO, 63110, USA."}], "LastName": "Yu", "ForeName": "Yanbo", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Radiology, Washington University School of Medicine, 510 S. Kingshighway Boulevard St. Louis, MO, 63110, USA."}], "LastName": "Tu", "ForeName": "Zhude", "Initials": "Z"}], "GrantList": [{"GrantID": "NS075527, NS103957, NS103988, U19NS110456", "Acronym": "NH", "Agency": "NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Pyrazoles"}, {"RegistryNumber": "3QD5KJZ7ZJ", "NameOfSubstance": "pyrazole"}], "MeshHeadingList": [{"QualifierName": ["drug therapy"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Parkinson Disease"}, {"QualifierName": ["chemical synthesis", "chemistry", "therapeutic use"], "DescriptorName": "Pyrazoles"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Giornal F., Pazenok S., Rodefeld L., Lui N., Vors J.P., Leroux F.R. Synthesis of diversely fluorinated pyrazoles as novel active agrochemical ingredients. J. Fluorine Chem. 2013;152:2\u201311. doi: 10.1016/j.jfluchem.2012.11.008.", "ArticleIdList": ["10.1016/j.jfluchem.2012.11.008"]}, {"Citation": "Khan M.F., Alam M.M., Verma G., Akhtar W., Akhter M., Shaquiquzzaman M. The therapeutic voyage of pyrazole and its analogs: A review. Eur. J. Med. Chem. 2016;120:170\u2013201. doi: 10.1016/j.ejmech.2016.04.077.", "ArticleIdList": ["10.1016/j.ejmech.2016.04.077", "27191614"]}, {"Citation": "Karrouchi K., Radi S., Ramli Y., Taoufik J., Mabkhot Y.N., Al-Aizari F.A., Ansar M. Synthesis and pharmacological activities of pyrazole derivatives: A review. Molecules. 2018;23:134. doi: 10.3390/molecules23010134.", "ArticleIdList": ["10.3390/molecules23010134", "PMC6017056", "29329257"]}, {"Citation": "Byon W., Garonzik S., Boyd R.A., Frost C.E. Apixaban: A clinical pharmacokinetic and pharmacodynamic review. Clin. Pharmacokinet. 2019;58:1265\u20131279. doi: 10.1007/s40262-019-00775-z.", "ArticleIdList": ["10.1007/s40262-019-00775-z", "PMC6769096", "31089975"]}, {"Citation": "Fustero S., Sanchez-Rosello M., Barrio P., Simon-Fuentes A. From 2000 to mid-2010: A fruitful decade for the synthesis of pyrazoles. Chem. Rev. 2011;111:6984\u20137034. doi: 10.1021/cr2000459.", "ArticleIdList": ["10.1021/cr2000459", "21806021"]}, {"Citation": "Gomes P.M.O., Silva A.M.S., Silva V.L.M. Pyrazoles as key scaffolds for the development of fluorine-18-labeled radiotracers for positron emission tomography (PET) Molecules. 2020;25:1722. doi: 10.3390/molecules25071722.", "ArticleIdList": ["10.3390/molecules25071722", "PMC7181023", "32283680"]}, {"Citation": "Turkan F., Cetin A., Taslimi P., Gulcin I. Some pyrazoles derivatives: Potent carbonic anhydrase, \u03b1-glycosidase, and cholinesterase enzymes inhibitors. Arch. Pharm. 2018;351:e1800200. doi: 10.1002/ardp.201800200.", "ArticleIdList": ["10.1002/ardp.201800200", "30246264"]}, {"Citation": "Hazarika R., Konwar M., Damarla K., Kumar A., Sarma D. HBF4/ACN: A simple and efficient protocol for the synthesis of pyrazoles under ambient reaction conditions. Synth. Commun. 2019;50:329\u2013337. doi: 10.1080/00397911.2019.1692869.", "ArticleIdList": ["10.1080/00397911.2019.1692869"]}, {"Citation": "Wang H.F., Sun X.L., Zhang S.L., Liu G.L., Wang C.J., Zhu L.L., Zhang H. Efficient copper-catalyzed synthesis of substituted pyrazoles at room temperature. Synlett. 2018;29:2689\u20132692. doi: 10.1055/s-0037-1610330.", "ArticleIdList": ["10.1055/s-0037-1610330"]}, {"Citation": "Kumar S.V., Yadav S.K., Raghava B., Saraiah B., Ila H., Rangappa K.S., Hazra A. Cyclocondensation of arylhydrazines with 1,3-bis(het)arylmonothio-1,3-diketones and 1,3-bis(het)aryl-3-(methylthio)-2-propenones: Synthesis of 1-aryl-3,5-bis(het)arylpyrazoles with complementary regioselectivity. J. Org. Chem. 2013;78:4960\u20134973. doi: 10.1021/jo400599e.", "ArticleIdList": ["10.1021/jo400599e", "23607788"]}, {"Citation": "Schmitt D.C., Taylor A.P., Flick A.C., Kyne R.E., Jr. Synthesis of pyrazoles from 1,3-diols via hydrogen transfer catalysis. Org. Lett. 2015;17:1405\u20131408. doi: 10.1021/acs.orglett.5b00266.", "ArticleIdList": ["10.1021/acs.orglett.5b00266", "25719568"]}, {"Citation": "Zhang X., Kang J., Niu P., Wu J., Yu W., Chang J. I2-mediated oxidative C-N bond formation for metal-free one-pot synthesis of di-, tri-, and tetrasubstituted pyrazoles from \u03b1,\u03b2-unsaturated aldehydes/ketones and hydrazines. J. Org. Chem. 2014;79:10170\u201310178. doi: 10.1021/jo501844x.", "ArticleIdList": ["10.1021/jo501844x", "25279429"]}, {"Citation": "Gutti G., Kumar D., Paliwal P., Ganeshpurkar A., Lahre K., Kumar A., Krishnamurthy S., Singh S.K. Development of pyrazole and spiropyrazoline analogs as multifunctional agents for treatment of Alzheimer\u2019s disease. Bioorg. Chem. 2019;90:103080. doi: 10.1016/j.bioorg.2019.103080.", "ArticleIdList": ["10.1016/j.bioorg.2019.103080", "31271946"]}, {"Citation": "Ding Y., Zhang T., Chen Q.Y., Zhu C. Visible-light photocatalytic aerobic annulation for the green synthesis of pyrazoles. Org. Lett. 2016;18:4206\u20134209. doi: 10.1021/acs.orglett.6b01867.", "ArticleIdList": ["10.1021/acs.orglett.6b01867", "27529570"]}, {"Citation": "Hu J., Chen S., Sun Y., Yang J., Rao Y. Synthesis of tri- and tetrasubstituted pyrazoles via Ru(II) catalysis: Intramolecular aerobic oxidative C-N coupling. Org. Lett. 2012;14:5030\u20135033. doi: 10.1021/ol3022353.", "ArticleIdList": ["10.1021/ol3022353", "22988906"]}, {"Citation": "Harigae R., Moriyama K., Togo H. Preparation of 3,5-disubstituted pyrazoles and isoxazoles from terminal alkynes, aldehydes, hydrazines, and hydroxylamine. J. Org. Chem. 2014;79:2049\u20132058. doi: 10.1021/jo4027116.", "ArticleIdList": ["10.1021/jo4027116", "24512630"]}, {"Citation": "Raji Reddy C., Vijaykumar J., Gr\u00e9e R. Facile one-pot synthesis of 3,5-disubstituted 1H-pyrazoles from propargylic alcohols via propargyl hydrazides. Synthesis. 2013;45:830\u2013836. doi: 10.1055/s-0032-1316856.", "ArticleIdList": ["10.1055/s-0032-1316856"]}, {"Citation": "Guo Y., Wang G., Wei L., Wan J.P. Domino C-H sulfonylation and pyrazole annulation for fully substituted pyrazole synthesis in water using hydrophilic enaminones. J. Org. Chem. 2019;84:2984\u20132990. doi: 10.1021/acs.joc.8b02897.", "ArticleIdList": ["10.1021/acs.joc.8b02897", "30714367"]}, {"Citation": "Raghunadh A., Meruva S.B., Mekala R., Rao K.R., Krishna T., Chary R.G., Rao L.V., Kumar U.K.S. An efficient regioselective copper catalyzed multi-component synthesis of 1,3-disubstituted pyrazoles. Tetrahedron Lett. 2014;55:2986\u20132990. doi: 10.1016/j.tetlet.2014.03.125.", "ArticleIdList": ["10.1016/j.tetlet.2014.03.125"]}, {"Citation": "Chen J., Properzi R., Uccello D.P., Young J.A., Dushin R.G., Starr J.T. One-pot oxidation and rearrangement of propargylamines and in situ pyrazole synthesis. Org. Lett. 2014;16:4146\u20134149. doi: 10.1021/ol501842b.", "ArticleIdList": ["10.1021/ol501842b", "25069029"]}, {"Citation": "Tang M., Zhang F.M. Efficient one-pot synthesis of substituted pyrazoles. Tetrahedron. 2013;69:1427\u20131433. doi: 10.1016/j.tet.2012.12.038.", "ArticleIdList": ["10.1016/j.tet.2012.12.038"]}, {"Citation": "Wen J., Fu Y., Zhang R.Y., Zhang J., Chen S.Y., Yu X.Q. A simple and efficient synthesis of pyrazoles in water. Tetrahedron. 2011;67:9618\u20139621. doi: 10.1016/j.tet.2011.09.074.", "ArticleIdList": ["10.1016/j.tet.2011.09.074"]}, {"Citation": "Zhang G., Ni H., Chen W., Shao J., Liu H., Chen B., Yu Y. One-pot three-component approach to the synthesis of polyfunctional pyrazoles. Org. Lett. 2013;15:5967\u20135969. doi: 10.1021/ol402810f.", "ArticleIdList": ["10.1021/ol402810f", "24255982"]}, {"Citation": "Sha Q., Wei Y.Y. An efficient one-pot synthesis of 3,5-diaryl-4-bromopyrazoles by 1,3-dipolar cycloaddition of in situ generated diazo compounds and 1-bromoalk-1-ynes. Synthesis. 2013;45:413\u2013420. doi: 10.1002/chin.201321127.", "ArticleIdList": ["10.1002/chin.201321127"]}, {"Citation": "Wang L., Huang J., Gong X., Wang J. Highly regioselective organocatalyzed synthesis of pyrazoles from diazoacetates and carbonyl compounds. Chem. Eur. J. 2013;19:7555\u20137560. doi: 10.1002/chem.201300047.", "ArticleIdList": ["10.1002/chem.201300047", "23576283"]}, {"Citation": "Jackowski O., Lecourt T., Micouin L. Direct synthesis of polysubstituted aluminoisoxazoles and pyrazoles by a metalative cyclization. Org. Lett. 2011;13:5664\u20135667. doi: 10.1021/ol202389u.", "ArticleIdList": ["10.1021/ol202389u", "21942717"]}, {"Citation": "Li D.Y., Mao X.F., Chen H.J., Chen G.R., Liu P.N. Rhodium-catalyzed addition-cyclization of hydrazines with alkynes: Pyrazole synthesis via unexpected C-N bond cleavage. Org. Lett. 2014;16:3476\u20133479. doi: 10.1021/ol501402p.", "ArticleIdList": ["10.1021/ol501402p", "24964008"]}, {"Citation": "Ledovskaya M.S., Voronin V.V., Polynski M.V., Lebedev A.N., Ananikov V.P. Primary vinyl ethers as acetylene surrogate: A flexible tool for deuterium-labeled pyrazole synthesis. Eur. J. Org. Chem. 2020;2020:4571\u20134580. doi: 10.1002/ejoc.202000674.", "ArticleIdList": ["10.1002/ejoc.202000674"]}, {"Citation": "Kobayashi E., Togo H. Facile one-pot transformation of primary alcohols into 3-aryl- and 3-alkyl-isoxazoles and -pyrazoles. Synthesis. 2019;51:3723\u20133735. doi: 10.1055/s-0039-1690102.", "ArticleIdList": ["10.1055/s-0039-1690102"]}, {"Citation": "Panda N., Jena A.K. Fe-catalyzed one-pot synthesis of 1,3-di- and 1,3,5-trisubstituted pyrazoles from hydrazones and vicinal diols. J. Org. Chem. 2012;77:9401\u20139406. doi: 10.1021/jo301770k.", "ArticleIdList": ["10.1021/jo301770k", "22998610"]}, {"Citation": "Fan X.W., Lei T., Zhou C., Meng Q.Y., Chen B., Tung C.H., Wu L.Z. Radical addition of hydrazones by \u03b1-bromo ketones to prepare 1,3,5-trisubstituted pyrazoles via visible light catalysis. J. Org. Chem. 2016;81:7127\u20137133. doi: 10.1021/acs.joc.6b00992.", "ArticleIdList": ["10.1021/acs.joc.6b00992", "27362866"]}, {"Citation": "Yi F., Zhao W., Wang Z., Bi X. Silver-mediated [3+2] cycloaddition of alkynes and N-isocyanoiminotriphenylphosphorane: Access to monosubstituted pyrazoles. Org. Lett. 2019;21:3158\u20133161. doi: 10.1021/acs.orglett.9b00860.", "ArticleIdList": ["10.1021/acs.orglett.9b00860", "30990050"]}, {"Citation": "Zhu J.N., Wang W.K., Jin Z.H., Wang Q.K., Zhao S.Y. Pyrrolo[3,4-c]pyrazole synthesis via copper(I) chloride-catalyzed oxidative coupling of hydrazones to maleimides. Org. Lett. 2019;21:5046\u20135050. doi: 10.1021/acs.orglett.9b01641.", "ArticleIdList": ["10.1021/acs.orglett.9b01641", "31247786"]}, {"Citation": "Specklin S., Decuypere E., Plougastel L., Aliani S., Taran F. One-pot synthesis of 1,4-disubstituted pyrazoles from arylglycines via copper-catalyzed sydnone-alkyne cycloaddition reaction. J. Org. Chem. 2014;79:7772\u20137777. doi: 10.1021/jo501420r.", "ArticleIdList": ["10.1021/jo501420r", "25054615"]}, {"Citation": "Lakeland C.P., Watson D.W., Harrity J.P.A. Exploiting synergistic catalysis for an ambient temperature photocycloaddition to pyrazoles. Chem. Eur. J. 2020;26:155\u2013159. doi: 10.1002/chem.201904210.", "ArticleIdList": ["10.1002/chem.201904210", "31657486"]}, {"Citation": "Zhang Q., Meng L.G., Wang K., Wang L. nBu3P-catalyzed desulfonylative [3 + 2] cycloadditions of allylic carbonates with arylazosulfones to pyrazole derivatives. Org. Lett. 2015;17:872\u2013875. doi: 10.1021/ol503735c.", "ArticleIdList": ["10.1021/ol503735c", "25651031"]}, {"Citation": "Zhang Y.C., Liu J., Jia X.S. Phosphine-free [3+2] cycloaddition of propargylamines with dialkyl azodicarboxylates: An efficient access to pyrazole backbone. Synthesis. 2018;50:3499\u20133505."}, {"Citation": "Pearce A.J., Harkins R.P., Reiner B.R., Wotal A.C., Dunscomb R.J., Tonks I.A. Multicomponent pyrazole synthesis from alkynes, nitriles, and titanium imido complexes via oxidatively induced N-N bond coupling. J. Am. Chem. Soc. 2020;142:4390\u20134399. doi: 10.1021/jacs.9b13173.", "ArticleIdList": ["10.1021/jacs.9b13173", "PMC7201868", "32043879"]}, {"Citation": "Sloop J.C., Holder C., Henary M. Selective incorporation of fluorine in pyrazoles. Eur. J. Org. Chem. 2015;2015:3405\u20133422. doi: 10.1002/ejoc.201500258.", "ArticleIdList": ["10.1002/ejoc.201500258"]}, {"Citation": "Prieto A., Bouyssi D., Monteiro N. Ruthenium-catalyzed tandem C-H fluoromethylation/cyclization of N-alkylhydrazones with CBr3F: Access to 4-fluoropyrazoles. J. Org. Chem. 2017;82:3311\u20133316. doi: 10.1021/acs.joc.7b00085.", "ArticleIdList": ["10.1021/acs.joc.7b00085", "28263600"]}, {"Citation": "Schmitt E., Panossian A., Vors J.P., Funke C., Lui N., Pazenok S., Leroux F.R. A major advance in the synthesis of fluoroalkyl pyrazoles: Tuneable regioselectivity and broad substitution patterns. Chem. Eur. J. 2016;22:11239\u201311244. doi: 10.1002/chem.201601621.", "ArticleIdList": ["10.1002/chem.201601621", "27362713"]}, {"Citation": "Schmitt E., Bouvet S., Pegot B., Panossian A., Vors J.P., Pazenok S., Magnier E., Leroux F.R. Fluoroalkyl amino reagents for the introduction of the fluoro(trifluoromethoxy)methyl group onto arenes and heterocycles. Org. Lett. 2017;19:4960\u20134963. doi: 10.1021/acs.orglett.7b02444.", "ArticleIdList": ["10.1021/acs.orglett.7b02444", "28862861"]}, {"Citation": "Mykhailiuk P.K. In situ generation of difluoromethyl diazomethane for [3+2] cycloadditions with alkynes. Angew. Chem. Int. Ed. 2015;54:6558\u20136561. doi: 10.1002/anie.201501529.", "ArticleIdList": ["10.1002/anie.201501529", "25801346"]}, {"Citation": "Montoya V., Pons J., Garc\u00eda-Ant\u00f3n J., Solans X., Font-Bardia M., Ros J. Reaction of 2-hydroxyethylhydrazine with a trifluoromethyl-\u03b2-diketone: Study and structural characterization of a new 5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazole intermediate. J. Fluorine Chem. 2007;128:1007\u20131011. doi: 10.1016/j.jfluchem.2007.04.027.", "ArticleIdList": ["10.1016/j.jfluchem.2007.04.027"]}, {"Citation": "Li F., Nie J., Sun L., Zheng Y., Ma J.A. Silver-mediated cycloaddition of alkynes with CF3CHN2: Highly regioselective synthesis of 3-trifluoromethylpyrazoles. Angew. Chem. Int. Ed. 2013;52:6255\u20136258. doi: 10.1002/anie.201301870.", "ArticleIdList": ["10.1002/anie.201301870", "23616303"]}, {"Citation": "Sun A., Chandrakumar N., Yoon J.-J., Plemper R.K., Snyder J.P. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. Bioorg. Med. Chem. Lett. 2007;17:5199\u20135203. doi: 10.1016/j.bmcl.2007.06.084.", "ArticleIdList": ["10.1016/j.bmcl.2007.06.084", "PMC2100383", "17643302"]}, {"Citation": "Ji G., Wang X., Zhang S., Xu Y., Ye Y., Li M., Zhang Y., Wang J. Synthesis of 3-trifluoromethylpyrazoles via trifluoromethylation/cyclization of \u03b1,\u03b2-alkynic hydrazones using a hypervalent iodine reagent. Chem. Commun. 2014;50:4361\u20134363. doi: 10.1039/C4CC01280A.", "ArticleIdList": ["10.1039/C4CC01280A", "24643782"]}, {"Citation": "50 Liu H., Laforest R., Gu J., Luo Z., Jones L.A., Gropler R.J., Benzinger T.L.S., Tu Z. Acute rodent tolerability, toxicity, and radiation dosimetry estimates of the S1P1-specific radioligand [11C]CS1P1. Mol. Imaging. Biol. 2020;22:285\u2013292. doi: 10.1007/s11307-019-01380-z.", "ArticleIdList": ["10.1007/s11307-019-01380-z", "PMC6893109", "31165387"]}, {"Citation": "Wang Q., He L., Li K.K., Tsui G.C. Copper-mediated domino cyclization/trifluoromethylation/deprotection with TMSCF3: Synthesis of 4-(trifluoromethyl)pyrazoles. Org. Lett. 2017;19:658\u2013661. doi: 10.1021/acs.orglett.6b03822.", "ArticleIdList": ["10.1021/acs.orglett.6b03822", "28080073"]}, {"Citation": "Trofymchuk S., Bugera M.Y., Klipkov A.A., Razhyk B., Semenov S., Tarasenko K., Starova V.S., Zaporozhets O.A., Tananaiko O.Y., Alekseenko A.N., et al. Deoxofluorination of (hetero)aromatic acids. J. Org. Chem. 2020;85:3110\u20133124. doi: 10.1021/acs.joc.9b03011.", "ArticleIdList": ["10.1021/acs.joc.9b03011", "31928000"]}, {"Citation": "Dhanju S., Caravana A.C., Thomson R.J. Access to \u03b1-pyrazole and \u03b1-triazole derivatives of ketones from oxidative heteroarylation of silyl enolethers. Org. Lett. 2020;22:8055\u20138058. doi: 10.1021/acs.orglett.0c03005.", "ArticleIdList": ["10.1021/acs.orglett.0c03005", "PMC7869407", "33000948"]}, {"Citation": "Kumar V., Kaur K., Gupta G.K., Sharma A.K. Pyrazole containing natural products: Synthetic preview and biological significance. Eur. J. Med. Chem. 2013;69:735\u2013753. doi: 10.1016/j.ejmech.2013.08.053.", "ArticleIdList": ["10.1016/j.ejmech.2013.08.053", "24099993"]}, {"Citation": "Luo G., Chen L. Gold-catalyzed stereoselective 1,4-conjugate addition of pyrazoles to propiolates and their hydrogenation to \u03b2-pyrazolyl acid esters. Tetrahedron Lett. 2015;56:6276\u20136278. doi: 10.1016/j.tetlet.2015.09.122.", "ArticleIdList": ["10.1016/j.tetlet.2015.09.122"]}, {"Citation": "Roughley S.D., Jordan A.M. The medicinal chemist\u2019s toolbox: An analysis of reactions used in the pursuit of drug candidates. J. Med. Chem. 2011;54:3451\u20133479. doi: 10.1021/jm200187y.", "ArticleIdList": ["10.1021/jm200187y", "21504168"]}, {"Citation": "Viciano-Chumillas M., Tanase S., de Jongh L.J., Reedijk J. Coordination versatility of pyrazole-based ligands towards high-nuclearity transition-metal and rare-earth clusters. Eur. J. Inorg. Chem. 2010;2010:3403\u20133418. doi: 10.1002/ejic.201000412.", "ArticleIdList": ["10.1002/ejic.201000412"]}, {"Citation": "Ruiz-Castillo P., Buchwald S.L. Applications of palladium-catalyzed C-N cross-coupling reactions. Chem. Rev. 2016;116:12564\u201312649. doi: 10.1021/acs.chemrev.6b00512.", "ArticleIdList": ["10.1021/acs.chemrev.6b00512", "PMC5070552", "27689804"]}, {"Citation": "Ma D., Cai Q., Zhang H. Mild method for Ullmann coupling reaction of amines and aryl halides. Org. Lett. 2003;5:2453\u20132455. doi: 10.1021/ol0346584.", "ArticleIdList": ["10.1021/ol0346584", "12841753"]}, {"Citation": "Onodera S., Kochi T., Kakiuchi F. Synthesis of N-arylpyrazoles by palladium-catalyzed coupling of aryl triflates with pyrazole derivatives. J. Org. Chem. 2019;84:6508\u20136515. doi: 10.1021/acs.joc.9b00673.", "ArticleIdList": ["10.1021/acs.joc.9b00673", "31026163"]}, {"Citation": "Zhou Q., Du F., Chen Y., Fu Y., Sun W., Wu Y., Chen G. L-(-)-Quebrachitol as a ligand for selective copper(0)-catalyzed N-arylation of nitrogen-containing heterocycles. J. Org. Chem. 2019;84:8160\u20138167. doi: 10.1021/acs.joc.9b00997.", "ArticleIdList": ["10.1021/acs.joc.9b00997", "31190531"]}, {"Citation": "Cristau H.-J., Cellier P.P., Spindler J.-F., Taillefer M. Mild conditions for copper-catalysed N-arylation of pyrazoles. Eur. J. Org. Chem. 2004;2004:695\u2013709. doi: 10.1002/ejoc.200300709.", "ArticleIdList": ["10.1002/ejoc.200300709"]}, {"Citation": "Wang J., Li J.H., Guo Y., Dong H., Liu Q., Yu X.Q. TEMPO-mediated C-H amination of benzoxazoles with N-heterocycles. J. Org. Chem. 2020;85:12797\u201312803. doi: 10.1021/acs.joc.0c01921.", "ArticleIdList": ["10.1021/acs.joc.0c01921", "32878444"]}, {"Citation": "Aggarwal R., Kumar V., Kumar R., Singh S.P. Approaches towards the synthesis of 5-aminopyrazoles. Beilstein J. Org. Chem. 2011;7:179\u2013197. doi: 10.3762/bjoc.7.25.", "ArticleIdList": ["10.3762/bjoc.7.25", "PMC3063075", "21448263"]}, {"Citation": "Senadi G.C., Hu W.P., Lu T.Y., Garkhedkar A.M., Vandavasi J.K., Wang J.J. I2-TBHP-catalyzed oxidative cross-coupling of N-sulfonyl hydrazones and isocyanides to 5-aminopyrazoles. Org. Lett. 2015;17:1521\u20131524. doi: 10.1021/acs.orglett.5b00398.", "ArticleIdList": ["10.1021/acs.orglett.5b00398", "25738730"]}, {"Citation": "Kallman N.J., Cole K.P., Koenig T.M., Buser J.Y., McFarland A.D., McNulty L.M., Mitchell D. Synthesis of aminopyrazoles from isoxazoles: Comparison of preparative methods by in situ NMR analysis. Synthesis. 2016;48:3537\u20133543."}, {"Citation": "Soriano-Garcia M. Organoselenium compounds as potential therapeutic and chemopreventive agents: A review. Curr. Med. Chem. 2004;11:1657\u20131669. doi: 10.2174/0929867043365053.", "ArticleIdList": ["10.2174/0929867043365053", "15180570"]}, {"Citation": "Gandin V., Khalkar P., Braude J., Fernandes A.P. Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment. Free Radic. Biol. Med. 2018;127:80\u201397. doi: 10.1016/j.freeradbiomed.2018.05.001.", "ArticleIdList": ["10.1016/j.freeradbiomed.2018.05.001", "29746900"]}, {"Citation": "Desai D., Kaushal N., Gandhi U.H., Arner R.J., D\u2019Souza C., Chen G., Vunta H., El-Bayoumy K., Amin S., Prabhu K.S. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem. Biol. Interact. 2010;188:446\u2013456. doi: 10.1016/j.cbi.2010.09.021.", "ArticleIdList": ["10.1016/j.cbi.2010.09.021", "PMC3004533", "20883674"]}, {"Citation": "Belladona A.L., Cervo R., Alves D., Barcellos T., Cargnelutti R., Schumacher R.F. C-H functionalization of (hetero)arenes: Direct selanylation mediated by Selectfluor. Tetrahedron Lett. 2020;61:152035. doi: 10.1016/j.tetlet.2020.152035.", "ArticleIdList": ["10.1016/j.tetlet.2020.152035"]}, {"Citation": "Wang X., Liu W.G., Tung C.H., Wu L.Z., Cong H. A monophosphine ligand derived from anthracene photodimer: Synthetic applications for palladium-catalyzed coupling reactions. Org. Lett. 2019;21:8158\u20138163. doi: 10.1021/acs.orglett.9b02414.", "ArticleIdList": ["10.1021/acs.orglett.9b02414", "31403303"]}, {"Citation": "Kirsten C.N., Schrader T.H. Intermolecular \u03b2-sheet stabilization with aminopyrazoles. J. Am. Chem. Soc. 1997;119:12061\u201312068. doi: 10.1021/ja972158y.", "ArticleIdList": ["10.1021/ja972158y"]}, {"Citation": "Rzepecki P., Schrader T. \u03b2-Sheet ligands in action: KLVFF recognition by aminopyrazole hybrid receptors in water. J. Am. Chem. Soc. 2005;127:3016\u20133025. doi: 10.1021/ja045558b.", "ArticleIdList": ["10.1021/ja045558b", "15740139"]}, {"Citation": "Frisoni G.B., Laakso M.P., Beltramello A., Geroldi C., Bianchetti A., Soininen H., Trabucchi M. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer\u2019s disease. Neurology. 1999;52:91\u2013100. doi: 10.1212/WNL.52.1.91.", "ArticleIdList": ["10.1212/WNL.52.1.91", "9921854"]}, {"Citation": "Hardy J.A., Higgins G.A. Alzheimer\u2019s disease: The amyloid cascade hypothesis. Science. 1992;256:184\u2013185. doi: 10.1126/science.1566067.", "ArticleIdList": ["10.1126/science.1566067", "1566067"]}, {"Citation": "Savelieff M.G., Nam G., Kang J., Lee H.J., Lee M., Lim M.H. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade. Chem. Rev. 2019;119:1221\u20131322. doi: 10.1021/acs.chemrev.8b00138.", "ArticleIdList": ["10.1021/acs.chemrev.8b00138", "30095897"]}, {"Citation": "Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer\u2019s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry. 1999;66:137\u2013147. doi: 10.1136/jnnp.66.2.137.", "ArticleIdList": ["10.1136/jnnp.66.2.137", "PMC1736202", "10071091"]}, {"Citation": "Fonnum F. Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities. Biochem. J. 1969;115:465\u2013472. doi: 10.1042/bj1150465.", "ArticleIdList": ["10.1042/bj1150465", "PMC1185125", "4982085"]}, {"Citation": "Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol. Ther. 2015;148:34\u201346. doi: 10.1016/j.pharmthera.2014.11.011.", "ArticleIdList": ["10.1016/j.pharmthera.2014.11.011", "25448037"]}, {"Citation": "Bartolini M., Bertucci C., Cavrini V., Andrisano V. \u03b2-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem. Pharmacol. 2003;65:407\u2013416. doi: 10.1016/S0006-2952(02)01514-9.", "ArticleIdList": ["10.1016/S0006-2952(02)01514-9", "12527333"]}, {"Citation": "Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scali C., Yu Q.S., Mamczarz J., Holloway H.W., Giordano T., et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer \u03b2-amyloid peptide in rodent. Proc. Natl. Acad. Sci. USA. 2005;102:17213\u201317218. doi: 10.1073/pnas.0508575102.", "ArticleIdList": ["10.1073/pnas.0508575102", "PMC1288010", "16275899"]}, {"Citation": "Nordberg A., Ballard C., Bullock R., Darreh-Shori T., Somogyi M. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer\u2019s disease. Prim. Care. Companion CNS Disord. 2013;15 doi: 10.4088/PCC.12r01412.", "ArticleIdList": ["10.4088/PCC.12r01412", "PMC3733526", "23930233"]}, {"Citation": "Shaikh S., Dhavan P., Pavale G., Ramana M.M.V., Jadhav B.L. Design, synthesis and evaluation of pyrazole bearing \u03b1-aminophosphonate derivatives as potential acetylcholinesterase inhibitors against Alzheimer\u2019s disease. Bioorg. Chem. 2020;96:103589\u2013103611. doi: 10.1016/j.bioorg.2020.103589.", "ArticleIdList": ["10.1016/j.bioorg.2020.103589", "31978679"]}, {"Citation": "Silva D., Chioua M., Samadi A., Carmo Carreiras M., Jimeno M.L., Mendes E., Rios Cde L., Romero A., Villarroya M., Lopez M.G., et al. Synthesis and pharmacological assessment of diversely substituted pyrazolo[3,4-b]quinoline, and benzo[b]pyrazolo[4,3-g][1,8]naphthyridine derivatives. Eur. J. Med. Chem. 2011;46:4676\u20134681. doi: 10.1016/j.ejmech.2011.05.068.", "ArticleIdList": ["10.1016/j.ejmech.2011.05.068", "21715067"]}, {"Citation": "Esch F.S., Keim P.S., Beattie E.C., Blacher R.W., Culwell A.R., Oltersdorf T., McClure D., Ward P.J. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990;248:1122\u20131124. doi: 10.1126/science.2111583.", "ArticleIdList": ["10.1126/science.2111583", "2111583"]}, {"Citation": "Zhang Y.W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer\u2019s disease. Mol. Brain. 2011;4:3\u201315. doi: 10.1186/1756-6606-4-3.", "ArticleIdList": ["10.1186/1756-6606-4-3", "PMC3022812", "21214928"]}, {"Citation": "Lee S.J., Nam E., Lee H.J., Savelieff M.G., Lim M.H. Towards an understanding of amyloid-\u03b2 oligomers: Characterization, toxicity mechanisms, and inhibitors. Chem. Soc. Rev. 2017;46:310\u2013323. doi: 10.1039/C6CS00731G.", "ArticleIdList": ["10.1039/C6CS00731G", "27878186"]}, {"Citation": "Kane M.D., Lipinski W.J., Callahan M.J., Bian F., Durham R.A., Schwarz R.D., Roher A.E., Walker L.C. Evidence for seeding of \u03b2-amyloid by intracerebral infusion of Alzheimer brain extracts in \u03b2-amyloid precursor protein-transgenic mice. J. Neurosci. 2000;20:3606\u20133611. doi: 10.1523/JNEUROSCI.20-10-03606.2000.", "ArticleIdList": ["10.1523/JNEUROSCI.20-10-03606.2000", "PMC6772682", "10804202"]}, {"Citation": "Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat. Rev. Neurosci. 2007;8:663\u2013672. doi: 10.1038/nrn2194.", "ArticleIdList": ["10.1038/nrn2194", "17684513"]}, {"Citation": "Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein \u03c4 (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA. 1986;83:4913\u20134917. doi: 10.1073/pnas.83.13.4913.", "ArticleIdList": ["10.1073/pnas.83.13.4913", "PMC323854", "3088567"]}, {"Citation": "Polydoro M., Acker C.M., Duff K., Castillo P.E., Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci. 2009;29:10741\u201310749. doi: 10.1523/JNEUROSCI.1065-09.2009.", "ArticleIdList": ["10.1523/JNEUROSCI.1065-09.2009", "PMC2760256", "19710325"]}, {"Citation": "Ward S.M., Himmelstein D.S., Lancia J.K., Binder L.I. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem. Soc. Trans. 2012;40:667\u2013671. doi: 10.1042/BST20120134.", "ArticleIdList": ["10.1042/BST20120134", "PMC3704193", "22817713"]}, {"Citation": "Hochdorffer K., Marz-Berberich J., Nagel-Steger L., Epple M., Meyer-Zaika W., Horn A.H., Sticht H., Sinha S., Bitan G., Schrader T. Rational design of \u03b2-sheet ligands against A\u03b242-induced toxicity. J. Am. Chem. Soc. 2011;133:4348\u20134358. doi: 10.1021/ja107675n.", "ArticleIdList": ["10.1021/ja107675n", "21381732"]}, {"Citation": "Wagner J., Ryazanov S., Leonov A., Levin J., Shi S., Schmidt F., Prix C., Pan-Montojo F., Bertsch U., Mitteregger-Kretzschmar G., et al. Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta. Neuropathol. 2013;125:795\u2013813. doi: 10.1007/s00401-013-1114-9.", "ArticleIdList": ["10.1007/s00401-013-1114-9", "PMC3661926", "23604588"]}, {"Citation": "Wagner J., Krauss S., Shi S., Ryazanov S., Steffen J., Miklitz C., Leonov A., Kleinknecht A., Goricke B., Weishaupt J.H., et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta. Neuropathol. 2015;130:619\u2013631. doi: 10.1007/s00401-015-1483-3.", "ArticleIdList": ["10.1007/s00401-015-1483-3", "PMC4612332", "26439832"]}, {"Citation": "Matthes D., Gapsys V., Griesinger C., de Groot B.L. Resolving the atomistic modes of anle138b inhibitory action on peptide oligomer formation. ACS Chem. Neurosci. 2017;8:2791\u20132808. doi: 10.1021/acschemneuro.7b00325.", "ArticleIdList": ["10.1021/acschemneuro.7b00325", "28906103"]}, {"Citation": "Belkacemi A., Doggui S., Dao L., Ramassamy C. Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev. Mol. Med. 2011;13:e34. doi: 10.1017/S1462399411002055.", "ArticleIdList": ["10.1017/S1462399411002055", "22051121"]}, {"Citation": "Mishra S., Patel S., Halpani C.G. Recent updates in curcumin pyrazole and isoxazole derivatives: Synthesis and biological application. Chem. Biodivers. 2019;16:e1800366. doi: 10.1002/cbdv.201800366.", "ArticleIdList": ["10.1002/cbdv.201800366", "30460748"]}, {"Citation": "Chainoglou E., Hadjipavlou-Litina D. Curcumin in health and diseases: Alzheimer\u2019s disease and curcumin analogues, derivatives, and hybrids. Int. J. Mol. Sci. 2020;21:1975. doi: 10.3390/ijms21061975.", "ArticleIdList": ["10.3390/ijms21061975", "PMC7139886", "32183162"]}, {"Citation": "Narlawar R., Pickhardt M., Leuchtenberger S., Baumann K., Krause S., Dyrks T., Weggen S., Mandelkow E., Schmidt B. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer\u2019s disease? ChemMedChem. 2008;3:165\u2013172. doi: 10.1002/cmdc.200700218.", "ArticleIdList": ["10.1002/cmdc.200700218", "17943713"]}, {"Citation": "Liu Y., Dargusch R., Maher P., Schubert D. A broadly neuroprotective derivative of curcumin. J. Neurochem. 2008;105:1336\u20131345. doi: 10.1111/j.1471-4159.2008.05236.x.", "ArticleIdList": ["10.1111/j.1471-4159.2008.05236.x", "18208543"]}, {"Citation": "Valera E., Dargusch R., Maher P.A., Schubert D. Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer\u2019s disease. J. Neurosci. 2013;33:10512\u201310525. doi: 10.1523/JNEUROSCI.5183-12.2013.", "ArticleIdList": ["10.1523/JNEUROSCI.5183-12.2013", "PMC3685841", "23785163"]}, {"Citation": "Kotani R., Urano Y., Sugimoto H., Noguchi N. Decrease of amyloid-\u03b2 levels by curcumin derivative via modulation of amyloid-\u03b2 protein precursor trafficking. J. Alzheimers Dis. 2017;56:529\u2013542. doi: 10.3233/JAD-160794.", "ArticleIdList": ["10.3233/JAD-160794", "27983550"]}, {"Citation": "Okuda M., Hijikuro I., Fujita Y., Teruya T., Kawakami H., Takahashi T., Sugimoto H. Design and synthesis of curcumin derivatives as tau and amyloid \u03b2 dual aggregation inhibitors. Bioorg. Med. Chem. Lett. 2016;26:5024\u20135028. doi: 10.1016/j.bmcl.2016.08.092.", "ArticleIdList": ["10.1016/j.bmcl.2016.08.092", "27624076"]}, {"Citation": "Okuda M., Fujita Y., Hijikuro I., Wada M., Uemura T., Kobayashi Y., Waku T., Tanaka N., Nishimoto T., Izumi Y., et al. PE859, a novel curcumin derivative, inhibits amyloid-\u03b2 and tau aggregation, and ameliorates cognitive dysfunction in senescence-accelerated mouse prone 8. J. Alzheimers. Dis. 2017;59:313\u2013328. doi: 10.3233/JAD-161017.", "ArticleIdList": ["10.3233/JAD-161017", "28598836"]}, {"Citation": "Menniti F.S., Faraci W.S., Schmidt C.J. Phosphodiesterases in the CNS: Targets for drug development. Nat. Rev. Drug. Discov. 2006;5:660\u2013670. doi: 10.1038/nrd2058.", "ArticleIdList": ["10.1038/nrd2058", "16883304"]}, {"Citation": "Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol. Rev. 2006;58:488\u2013520. doi: 10.1124/pr.58.3.5.", "ArticleIdList": ["10.1124/pr.58.3.5", "16968949"]}, {"Citation": "Prickaerts J., Heckman P.R.A., Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease. Expert. Opin. Investig. Drugs. 2017;26:1033\u20131048. doi: 10.1080/13543784.2017.1364360.", "ArticleIdList": ["10.1080/13543784.2017.1364360", "28772081"]}, {"Citation": "Cuadrado-Tejedor M., Hervias I., Ricobaraza A., Puerta E., Perez-Roldan J.M., Garcia-Barroso C., Franco R., Aguirre N., Garcia-Osta A. Sildenafil restores cognitive function without affecting \u03b2-amyloid burden in a mouse model of Alzheimer\u2019s disease. Br. J. Pharmacol. 2011;164:2029\u20132041. doi: 10.1111/j.1476-5381.2011.01517.x.", "ArticleIdList": ["10.1111/j.1476-5381.2011.01517.x", "PMC3246665", "21627640"]}, {"Citation": "Heckman P.R., Wouters C., Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer\u2019s disease: A translational overview. Curr. Pharm. Des. 2015;21:317\u2013331. doi: 10.2174/1381612820666140826114601.", "ArticleIdList": ["10.2174/1381612820666140826114601", "25159073"]}, {"Citation": "Li P., Zheng H., Zhao J., Zhang L., Yao W., Zhu H., Beard J.D., Ida K., Lane W., Snell G., et al. Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases. J. Med. Chem. 2016;59:1149\u20131164. doi: 10.1021/acs.jmedchem.5b01751.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01751", "26789933"]}, {"Citation": "Lakics V., Karran E.H., Boess F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010;59:367\u2013374. doi: 10.1016/j.neuropharm.2010.05.004.", "ArticleIdList": ["10.1016/j.neuropharm.2010.05.004", "20493887"]}, {"Citation": "Shimizu-Albergine M., Rybalkin S.D., Rybalkina I.G., Feil R., Wolfsgruber W., Hofmann F., Beavo J.A. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): In vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J. Neurosci. 2003;23:6452\u20136459. doi: 10.1523/JNEUROSCI.23-16-06452.2003.", "ArticleIdList": ["10.1523/JNEUROSCI.23-16-06452.2003", "PMC6740622", "12878685"]}, {"Citation": "Puzzo D., Staniszewski A., Deng S.X., Privitera L., Leznik E., Liu S., Zhang H., Feng Y., Palmeri A., Landry D.W., et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-\u03b2 load in an Alzheimer\u2019s disease mouse model. J. Neurosci. 2009;29:8075\u20138086. doi: 10.1523/JNEUROSCI.0864-09.2009.", "ArticleIdList": ["10.1523/JNEUROSCI.0864-09.2009", "PMC6666028", "19553447"]}, {"Citation": "Zhang J., Guo J., Zhao X., Chen Z., Wang G., Liu A., Wang Q., Zhou W., Xu Y., Wang C. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav. Brain Res. 2013;250:230\u2013237. doi: 10.1016/j.bbr.2013.05.017.", "ArticleIdList": ["10.1016/j.bbr.2013.05.017", "23685322"]}, {"Citation": "Schultheiss D., Muller S.V., Nager W., Stief C.G., Schlote N., Jonas U., Asvestis C., Johannes S., Munte T.F. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: A study with event-related brain potentials. World J. Urol. 2001;19:46\u201350. doi: 10.1007/PL00007092.", "ArticleIdList": ["10.1007/PL00007092", "11289570"]}, {"Citation": "Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 1998;273:15559\u201315564. doi: 10.1074/jbc.273.25.15559.", "ArticleIdList": ["10.1074/jbc.273.25.15559", "9624146"]}, {"Citation": "Kleiman R.J., Chapin D.S., Christoffersen C., Freeman J., Fonseca K.R., Geoghegan K.F., Grimwood S., Guanowsky V., Hajos M., Harms J.F., et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J. Pharmacol. Exp. Ther. 2012;341:396\u2013409. doi: 10.1124/jpet.111.191353.", "ArticleIdList": ["10.1124/jpet.111.191353", "22328573"]}, {"Citation": "Verhoest P.R., Fonseca K.R., Hou X., Proulx-Lafrance C., Corman M., Helal C.J., Claffey M.M., Tuttle J.B., Coffman K.J., Liu S., et al. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyr an-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J. Med. Chem. 2012;55:9045\u20139054.", "ArticleIdList": ["22780914"]}, {"Citation": "Schwam E.M., Nicholas T., Chew R., Billing C.B., Davidson W., Ambrose D., Altstiel L.D. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer\u2019s disease. Curr. Alzheimer Res. 2014;11:413\u2013421. doi: 10.2174/1567205011666140505100858.", "ArticleIdList": ["10.2174/1567205011666140505100858", "24801218"]}, {"Citation": "Moschetti V., Boland K., Feifel U., Hoch A., Zimdahl-Gelling H., Sand M. First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males. Br. J. Clin. Pharmacol. 2016;82:1315\u20131324. doi: 10.1111/bcp.13060.", "ArticleIdList": ["10.1111/bcp.13060", "PMC5061793", "27378314"]}, {"Citation": "Rosenbrock H., Giovannini R., Schanzle G., Koros E., Runge F., Fuchs H., Marti A., Reymann K.G., Schroder U.H., Fedele E., et al. The novel phosphodiesterase 9A inhibitor BI 409306 increases cyclic guanosine monophosphate levels in the brain, promotes synaptic plasticity, and enhances memory function in rodents. J. Pharmacol. Exp. Ther. 2019;371:633\u2013641. doi: 10.1124/jpet.119.260059.", "ArticleIdList": ["10.1124/jpet.119.260059", "31578258"]}, {"Citation": "Ghosh A.S., Wang B., Pozniak C.D., Chen M., Watts R.J., Lewcock J.W. DLK induces developmental neuronal degeneration via selective regulation of proapoptotic JNK activity. J. Cell. Biol. 2011;194:751\u2013764. doi: 10.1083/jcb.201103153.", "ArticleIdList": ["10.1083/jcb.201103153", "PMC3171129", "21893599"]}, {"Citation": "Pozniak C.D., Sengupta Ghosh A., Gogineni A., Hanson J.E., Lee S.H., Larson J.L., Solanoy H., Bustos D., Li H., Ngu H., et al. Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration. J. Exp. Med. 2013;210:2553\u20132567. doi: 10.1084/jem.20122832.", "ArticleIdList": ["10.1084/jem.20122832", "PMC3832926", "24166713"]}, {"Citation": "Le Pichon C.E., Meilandt W.J., Dominguez S., Solanoy H., Lin H., Ngu H., Gogineni A., Sengupta Ghosh A., Jiang Z., Lee S.H., et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci. Transl. Med. 2017;9:eaag0394. doi: 10.1126/scitranslmed.aag0394.", "ArticleIdList": ["10.1126/scitranslmed.aag0394", "28814543"]}, {"Citation": "Patel S., Cohen F., Dean B.J., De La Torre K., Deshmukh G., Estrada A.A., Ghosh A.S., Gibbons P., Gustafson A., Huestis M.P., et al. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J. Med. Chem. 2015;58:401\u2013418. doi: 10.1021/jm5013984.", "ArticleIdList": ["10.1021/jm5013984", "25341110"]}, {"Citation": "Patel S., Harris S.F., Gibbons P., Deshmukh G., Gustafson A., Kellar T., Lin H., Liu X., Liu Y., Liu Y., et al. Scaffold-hopping and structure-based discovery of potent, selective, and brain penetrant N-(1H-pyrazol-3-yl)pyridin-2-amine inhibitors of dual leucine zipper kinase (DLK, MAP3K12) J. Med. Chem. 2015;58:8182\u20138199. doi: 10.1021/acs.jmedchem.5b01072.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01072", "26431428"]}, {"Citation": "Patel S., Meilandt W.J., Erickson R.I., Chen J., Deshmukh G., Estrada A.A., Fuji R.N., Gibbons P., Gustafson A., Harris S.F., et al. Selective inhibitors of dual leucine zipper kinase (DLK, MAP3K12) with activity in a model of Alzheimer\u2019s disease. J. Med. Chem. 2017;60:8083\u20138102. doi: 10.1021/acs.jmedchem.7b00843.", "ArticleIdList": ["10.1021/acs.jmedchem.7b00843", "28929759"]}, {"Citation": "Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: From genes to behavior. Annu. Rev. Neurosci. 1999;22:197\u2013217. doi: 10.1146/annurev.neuro.22.1.197.", "ArticleIdList": ["10.1146/annurev.neuro.22.1.197", "PMC2844879", "10202537"]}, {"Citation": "Sherif F., Gottfries C.G., Alafuzoff I., Oreland L. Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer\u2019s disease. J. Neural. Transm. 1992;4:227\u2013240. doi: 10.1007/BF02260906.", "ArticleIdList": ["10.1007/BF02260906", "1627256"]}, {"Citation": "Kennedy B.P., Ziegler M.G., Alford M., Hansen L.A., Thal L.J., Masliah E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer\u2019s disease. J. Neural. Transm. 2003;110:789\u2013801. doi: 10.1007/s00702-003-0828-6.", "ArticleIdList": ["10.1007/s00702-003-0828-6", "12811639"]}, {"Citation": "Saura J., Luque J.M., Cesura A.M., Prada M.D., Chan-Palay V., Huber G., L\u00f6ffler J., Richards J.G. Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62:15\u201330. doi: 10.1016/0306-4522(94)90311-5.", "ArticleIdList": ["10.1016/0306-4522(94)90311-5", "7816197"]}, {"Citation": "Zhao Y., Zhao B. Oxidative stress and the pathogenesis of alzheimer\u2019s disease. Oxid. Med. Cell.Longev. 2013;2013:316523. doi: 10.1155/2013/316523.", "ArticleIdList": ["10.1155/2013/316523", "PMC3745981", "23983897"]}, {"Citation": "Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease. N. Engl. J. Med. 1997;336:1216\u20131222. doi: 10.1056/NEJM199704243361704.", "ArticleIdList": ["10.1056/NEJM199704243361704", "9110909"]}, {"Citation": "Pisani L., Catto M., Leonetti F., Nicolotti O., Stefanachi A., Campagna F., Carotti A. Targeting monoamine oxidases with multipotent ligands: An emerging strategy in the search of new drugs against neurodegenerative diseases. Cur. Med. Chem. 2011;18:4568\u20134587. doi: 10.2174/092986711797379302.", "ArticleIdList": ["10.2174/092986711797379302", "21864289"]}, {"Citation": "Sterling J., Herzig Y., Goren T., Finkelstein N., Lerner D., Goldenberg W., Miskolczi I., Molnar S., Rantal F., Tamas T., et al. Novel Dual Inhibitors of AChE and MAO Derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer\u2019s disease. J. Med. Chem. 2002;45:5260\u20135279. doi: 10.1021/jm020120c.", "ArticleIdList": ["10.1021/jm020120c", "12431053"]}, {"Citation": "Huang L., Lu C., Sun Y., Mao F., Luo Z., Su T., Jiang H., Shan W., Li X. Multitarget-directed benzylideneindanone derivatives: Anti-\u03b2-amyloid (A\u03b2) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer\u2019s disease. J. Med. Chem. 2012;55:8483\u20138492. doi: 10.1021/jm300978h.", "ArticleIdList": ["10.1021/jm300978h", "22978824"]}, {"Citation": "Tzvetkov N.T., Antonov L. Subnanomolar indazole-5-carboxamide inhibitors of monoamine oxidase B (MAO-B) continued: Indications of iron binding, experimental evidence for optimised solubility and brain penetration. J. Enzyme Inhib. Med. Chem. 2017;32:960\u2013967. doi: 10.1080/14756366.2017.1344980.", "ArticleIdList": ["10.1080/14756366.2017.1344980", "PMC6445166", "28726524"]}, {"Citation": "Jayaraj R.L., Elangovan N., Dhanalakshmi C., Manivasagam T., Essa M.M. CNB-001, a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson\u2019s disease mice. Chem. Biol. Interact. 2014;220:149\u2013157. doi: 10.1016/j.cbi.2014.06.022.", "ArticleIdList": ["10.1016/j.cbi.2014.06.022", "24995576"]}, {"Citation": "Ahsan N., Mishra S., Jain M.K., Surolia A., Gupta S. Curcumin pyrazole and its derivative (N-(3-nitrophenylpyrazole) curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of wild type and mutant \u03b1-synuclein. Sci. Rep. 2015;5:9862. doi: 10.1038/srep09862.", "ArticleIdList": ["10.1038/srep09862", "PMC4435243", "25985292"]}, {"Citation": "Deeg A.A., Reiner A.M., Schmidt F., Schueder F., Ryazanov S., Ruf V.C., Giller K., Becker S., Leonov A., Griesinger C., et al. Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to \u03b1-synuclein aggregates. Biochim. Biophys. Acta. 2015;1850:1884\u20131890. doi: 10.1016/j.bbagen.2015.05.021.", "ArticleIdList": ["10.1016/j.bbagen.2015.05.021", "26028294"]}, {"Citation": "Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 1999;59:355\u2013396. doi: 10.1016/S0301-0082(99)00011-8.", "ArticleIdList": ["10.1016/S0301-0082(99)00011-8", "10501634"]}, {"Citation": "Schwarzschild M.A., Xu K., Oztas E., Petzer J.P., Castagnoli K., Castagnoli N., Jr., Chen J.F. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson\u2019s disease. Neurology. 2003;61:S55\u2013S61. doi: 10.1212/01.WNL.0000095214.53646.72.", "ArticleIdList": ["10.1212/01.WNL.0000095214.53646.72", "14663012"]}, {"Citation": "Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., Chase T.N. Adenosine A2A receptor antagonist treatment of Parkinson\u2019s disease. Neurology. 2003;61:293\u2013296. doi: 10.1212/01.WNL.0000073136.00548.D4.", "ArticleIdList": ["10.1212/01.WNL.0000073136.00548.D4", "12913186"]}, {"Citation": "Armentero M.T., Pinna A., Ferre S., Lanciego J.L., Muller C.E., Franco R. Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson\u2019s disease. Pharmacol. Ther. 2011;132:280\u2013299. doi: 10.1016/j.pharmthera.2011.07.004.", "ArticleIdList": ["10.1016/j.pharmthera.2011.07.004", "PMC3205226", "21810444"]}, {"Citation": "Yang Z., Li X., Ma H., Zheng J., Zhen X., Zhang X. Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists. Bioorg. Med. Chem. Lett. 2014;24:152\u2013155. doi: 10.1016/j.bmcl.2013.11.051.", "ArticleIdList": ["10.1016/j.bmcl.2013.11.051", "24332624"]}, {"Citation": "Zheng J., Yang Z., Li X., Li L., Ma H., Wang M., Zhang H., Zhen X., Zhang X. Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson\u2019s disease. ACS Chem. Neurosci. 2014;5:674\u2013682. doi: 10.1021/cn5000716.", "ArticleIdList": ["10.1021/cn5000716", "PMC4140592", "24922583"]}, {"Citation": "Yang Z., Li L., Zheng J., Ma H., Tian S., Li J., Zhang H., Zhen X., Zhang X. Identification of a new series of potent adenosine A2A receptor antagonists based on 4-amino-5-carbonitrile pyrimidine template for the treatment of Parkinson\u2019s disease. ACS Chem. Neurosci. 2016;7:1575\u20131584. doi: 10.1021/acschemneuro.6b00218.", "ArticleIdList": ["10.1021/acschemneuro.6b00218", "27569066"]}, {"Citation": "Soderling S.H., Bayuga S.J., Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA. 1999;96:7071\u20137076. doi: 10.1073/pnas.96.12.7071.", "ArticleIdList": ["10.1073/pnas.96.12.7071", "PMC22059", "10359840"]}, {"Citation": "Sancesario G., Morrone L.A., D\u2019Angelo V., Castelli V., Ferrazzoli D., Sica F., Martorana A., Sorge R., Cavaliere F., Bernardi G., et al. Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism? Neurochem. Int. 2014;79:44\u201356. doi: 10.1016/j.neuint.2014.10.004.", "ArticleIdList": ["10.1016/j.neuint.2014.10.004", "25452081"]}, {"Citation": "Niccolini F., Foltynie T., Reis Marques T., Muhlert N., Tziortzi A.C., Searle G.E., Natesan S., Kapur S., Rabiner E.A., Gunn R.N., et al. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson\u2019s disease. Brain. 2015;138:3003\u20133015. doi: 10.1093/brain/awv219.", "ArticleIdList": ["10.1093/brain/awv219", "26210536"]}, {"Citation": "Movsesian M., Stehlik J., Vandeput F., Bristow M.R. Phosphodiesterase inhibition in heart failure. Heart Fail. Rev. 2009;14:255\u2013263. doi: 10.1007/s10741-008-9130-x.", "ArticleIdList": ["10.1007/s10741-008-9130-x", "19096931"]}, {"Citation": "Heaslip R.J., Evans D.Y. Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur. J. Pharmacol. 1995;286:281\u2013290. doi: 10.1016/0014-2999(95)00457-2.", "ArticleIdList": ["10.1016/0014-2999(95)00457-2", "8608790"]}, {"Citation": "Verhoest P.R., Chapin D.S., Corman M., Fonseca K., Harms J.F., Hou X., Marr E.S., Menniti F.S., Nelson F., O\u2019Connor R., et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J. Med. Chem. 2009;52:5188\u20135196. doi: 10.1021/jm900521k.", "ArticleIdList": ["10.1021/jm900521k", "19630403"]}, {"Citation": "Li J., Jin H., Zhou H., Rothfuss J., Tu Z. Synthesis and in vitro biological evaluation of pyrazole group-containing analogues for PDE10A. MedChemComm. 2013;4:443\u2013449. doi: 10.1039/c2md20239e.", "ArticleIdList": ["10.1039/c2md20239e", "PMC3625062", "23585921"]}, {"Citation": "Li J., Zhang X., Jin H., Fan J., Flores H., Perlmutter J.S., Tu Z. Synthesis of fluorine-containing phosphodiesterase 10a (PDE10A) inhibitors and the in vivo evaluation of F-18 labeled PDE10A PET tracers in rodent and nonhuman primate. J. Med. Chem. 2015;58:8584\u20138600. doi: 10.1021/acs.jmedchem.5b01205.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01205", "PMC4697445", "26430878"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "1", "Day": "11"}, {"Year": "2021", "Month": "2", "Day": "20"}, {"Year": "2021", "Month": "2", "Day": "22"}, {"Year": "2021", "Month": "3", "Day": "6", "Hour": "1", "Minute": "1"}, {"Year": "2021", "Month": "3", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "2", "Day": "24"}], "PublicationStatus": "epublish", "ArticleIdList": ["33668128", "PMC7956461", "10.3390/molecules26051202", "molecules26051202"]}}], "PubmedBookArticle": []}